LGD-4033 (Ligandrol) + MK-677 (Ibutamoren) + MK-777 (Acetamoren) | SARMs & Growth-Factor Research UK

Androgen & Growth-Factor Signalling Research Set

The BioPlex Androgen & Growth-Factor Signalling Research Set combines LGD-4033 (Ligandrol) 50×15mg, MK-677 (Ibutamoren) 50×15mg and MK-777 (Acetamoren) 50×15mg, creating a three-compound research format spanning selective androgen-receptor signalling and growth-hormone-secretagogue-associated research. The set contains one pot of each compound and is designed around comparative investigation of different molecular pathways rather than treating all three compounds as pharmacologically identical.

LGD-4033 is a genuine non-steroidal selective androgen receptor modulator. Its research history centres on androgen-receptor binding, tissue-selective signalling and downstream androgen-responsive pathways.

MK-677 belongs to a fundamentally different pharmacological category. Also known as Ibutamoren, it is a non-peptide growth hormone secretagogue and established agonist of the ghrelin receptor, GHS-R1a. Research involving MK-677 has examined growth-hormone secretion, downstream IGF-1-associated signalling and broader endocrine and metabolic variables.

MK-777, commonly known as Acetamoren, provides the third component. It is an emerging small-molecule research compound frequently positioned alongside MK-677 within the research market. However, its direct compound-specific evidence remains substantially less developed than the evidence available for Ibutamoren.

The Androgen & Growth-Factor Signalling Research Set therefore brings together one established androgen-receptor pathway with two compounds associated commercially with growth-hormone-secretagogue research, while maintaining appropriate distinction between their respective evidence levels.

The name reflects the scientific pathways represented within the set rather than guaranteeing a particular combined outcome. Each compound remains independently identified, enabling researchers to separate established pharmacology from newer hypotheses while examining multiple signalling systems within one structured research framework.

How LGD-4033, MK-677 and MK-777 Work Together

LGD-4033, MK-677 and MK-777 create a multi-pathway research combination because they are associated with different areas of molecular and endocrine signalling. The principal distinction is between LGD-4033's established androgen-receptor activity and the growth-hormone-secretagogue-associated research surrounding MK-677 and MK-777.

LGD-4033 interacts with the androgen receptor, a ligand-regulated nuclear receptor involved in androgen-responsive transcription. As a non-steroidal selective androgen receptor modulator, Ligandrol has been investigated to determine how synthetic ligands can influence androgen-receptor activity and generate tissue-dependent experimental responses.

MK-677 operates through a different established pathway. Ibutamoren is an agonist of the growth hormone secretagogue receptor, commonly called GHS-R1a or the ghrelin receptor. Activation of this receptor has been investigated in relation to growth-hormone secretion and downstream endocrine markers including insulin-like growth factor-1.

MK-777 is frequently associated with a similar commercial research category to MK-677, but the evidence surrounding Acetamoren is considerably thinner. It should therefore not automatically be assumed to possess identical receptor affinity, signalling characteristics or downstream activity to Ibutamoren.

This makes the triple set useful for comparative pathway investigation. LGD-4033 provides a clearly characterised androgen-receptor component, MK-677 provides an established ghrelin-receptor and growth-hormone-secretagogue component, and MK-777 introduces an emerging compound requiring more cautious experimental interpretation.

The combination itself does not establish synergy between the three compounds. Nor should evidence involving LGD-4033 or MK-677 automatically be transferred to MK-777.

The scientific value instead lies in examining different signalling pathways within a common research framework while maintaining compound-specific controls, appropriate analytical identification and clear separation between established findings and emerging research hypotheses.

LGD-4033 (Ligandrol) 50×15mg

LGD-4033, commonly known as Ligandrol and also associated with the developmental identifier VK5211, is a synthetic non-steroidal selective androgen receptor modulator. It represents the androgen-receptor-focused component of the BioPlex Androgen & Growth-Factor Signalling Research Set.

The androgen receptor belongs to the nuclear-receptor superfamily and functions as a ligand-regulated transcription factor. Interaction between an appropriate ligand and the receptor can alter receptor conformation, co-regulator recruitment and subsequent expression of androgen-responsive genes.

LGD-4033 has been investigated as a high-affinity androgen-receptor ligand and forms part of the broader scientific effort to understand whether non-steroidal compounds can generate tissue-selective patterns of androgen-receptor activity.

Its research history is substantially different from that of MK-677. Although both compounds are frequently sold within commercial SARMs categories, MK-677 does not primarily interact with the androgen receptor and should not be classified as a SARM.

This distinction makes LGD-4033 particularly valuable within this three-compound set. It establishes a clearly defined androgen-receptor research pathway against which the different endocrine-signalling research surrounding MK-677 can be considered.

MK-777 introduces a further research question because its compound-specific evidence base remains much less developed.

Researchers should therefore avoid treating the three molecules as interchangeable or assuming that their placement within one set means they share the same mechanism.

Within the Androgen & Growth-Factor Signalling Research Set, LGD-4033 provides the established SARM component. Its receptor pharmacology, tissue-selective research history and androgen-responsive endpoints can be examined independently while researchers separately investigate growth-hormone-secretagogue-associated pathways represented by the other compounds.

This creates a broader comparative research framework than a set containing three molecules targeting only the androgen receptor.

MK-677 (Ibutamoren) 50×15mg

MK-677, commonly known as Ibutamoren and also identified as MK-0677 or L-163,191, is a synthetic non-peptide growth hormone secretagogue. Unlike LGD-4033, MK-677 is not a selective androgen receptor modulator and does not derive its principal research activity from androgen-receptor signalling.

Its established molecular target is the growth hormone secretagogue receptor, commonly known as GHS-R1a or the ghrelin receptor. Ghrelin acts as an endogenous ligand within this receptor system, while MK-677 has been investigated as a synthetic agonist capable of activating ghrelin-receptor-associated signalling.

Research involving Ibutamoren has examined growth-hormone secretion and downstream endocrine markers including insulin-like growth factor-1. Experimental research has also explored appetite-associated signalling, metabolic variables, sleep-related measurements, body-composition endpoints and other physiological processes associated with the broader ghrelin and growth-hormone signalling systems.

This relatively developed research history makes MK-677 useful as the established growth-hormone-secretagogue component of this triple set.

Its inclusion alongside LGD-4033 creates a clear mechanistic contrast. Ligandrol provides selective androgen-receptor modulation, whereas Ibutamoren provides ghrelin-receptor agonism and growth-hormone-secretagogue research.

MK-777 then provides an emerging third comparison associated commercially with related research themes but supported by a much smaller direct evidence base.

Within the Androgen & Growth-Factor Signalling Research Set, MK-677 should therefore be considered independently rather than being grouped pharmacologically with LGD-4033 simply because both compounds appear within the wider BioPlex capsule research range.

Its established receptor classification provides researchers with a defined molecular pathway that can be investigated alongside androgen-receptor signalling while retaining separate experimental controls and endpoints.

This distinction supports more accurate comparative research and prevents commercial product categorisation from being mistaken for scientific classification.

MK-777 (Acetamoren) 50×15mg

MK-777, commonly referred to as Acetamoren, is an emerging synthetic small-molecule research compound that has increasingly appeared within research-compound catalogues alongside MK-677 Ibutamoren and compounds commercially grouped within SARMs ranges.

The available evidence surrounding MK-777 requires substantially greater caution than the evidence available for either LGD-4033 or MK-677.

LGD-4033 possesses an established research classification as a selective androgen receptor modulator, while MK-677 has a documented pharmacological relationship with the growth hormone secretagogue receptor GHS-R1a. MK-777 does not currently possess an equivalent publicly accessible body of compound-specific pharmacological research.

Acetamoren is frequently positioned commercially within growth-hormone-secretagogue-associated research and compared with MK-677. However, commercial classification or naming similarity should not be treated as proof that MK-777 possesses identical receptor affinity, potency, pharmacokinetics or downstream signalling behaviour to Ibutamoren.

This evidence distinction is particularly important within the Androgen & Growth-Factor Signalling Research Set.

MK-777 provides an emerging research component that can be considered alongside two better-characterised reference compounds. LGD-4033 establishes the androgen-receptor pathway, while MK-677 establishes the recognised ghrelin-receptor and growth-hormone-secretagogue pathway.

Researchers investigating MK-777 can therefore distinguish observations involving Acetamoren from the established pharmacology of the other compounds rather than transferring findings from MK-677 directly onto MK-777.

The scientific value of MK-777 within this combination consequently comes partly from the unanswered questions surrounding its classification and molecular activity.

Careful compound identification, appropriate experimental controls and independent interpretation remain particularly important. This allows emerging MK-777 research to develop without overstating the current evidence or presenting proposed mechanisms as though they were already established pharmacological facts.

Explore Related Research Compounds

Continue exploring related androgen-receptor and growth-hormone-secretagogue research compounds from the BioPlex capsule range.

View LGD-4033 Ligandrol 50×15mg Research Capsules ⟶

View MK-677 Ibutamoren 50×15mg Research Capsules ⟶

View MK-777 Acetamoren 50×15mg Research Capsules ⟶

Explore BioPlex Research Information

Access BioPlex SARMs guidance, compound classification and the complete research product range.

Read the Complete SARMs UK Research Compound Guide ⟶

Explore the BioPlex SARMs & Research Compound Range ⟶

View All BioPlex Research Products ⟶

Explore Related Research Articles

Continue your research with BioPlex articles covering LGD-4033, MK-677, MK-777, androgen-receptor activity and growth-hormone-secretagogue research.

Read the MK-677 Ibutamoren Research Overview ⟶

Read the MK-777 Acetamoren Research Overview ⟶

Read MK-777 vs MK-677: Research Pathways & Key Differences ⟶

Explore All BioPlex SARMs Research Articles ⟶

Disclaimer

For research purposes only. Not for human consumption